About: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2008 (fr) наукова стаття, опублікована в листопаді 2008 (uk) im November 2008 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en payares de 2008 (ast) scientific article published on 01 November 2008 (en)
publication date	wds:Q79765442-FD86EDA4-DD98-4836-8892-EF85B648D67C
publication date	2008-11-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q79765442-36EBE26B-896D-4CC0-ABF2-2BC4ADE6BCEB wds:Q79765442-3A892EDF-0659-4B15-914F-8C4CABE718D1 wds:Q79765442-6237ACDB-CCC0-4F8F-967E-D10B17A5048B wds:Q79765442-AB64C50E-4C0D-4C32-9505-69E00FAD1650 wds:Q79765442-F3A3BBD4-F4AF-4F33-B774-1FFD2BDF2B72 wds:Q79765442-F5A505E2-3997-4FDA-82EC-D0AE344780E6
author name string	David Mason Robert Landewé Philip Mease Ronald Van Vollenhoven Chintu Desai Désireé van der Heijde
rdfs:label	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (en) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (nl)
skos:prefLabel	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (en) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (nl)
name	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (en) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (nl)
author	wds:Q79765442-4FECBA67-8E7D-4986-94C7-54A12C5A497B wds:Q79765442-8D4D00C3-576C-4E47-9C61-401F511069D5 wds:Q79765442-9C550B20-E0B5-490E-9121-481345DD7DB4 wds:Q79765442-B1D9F737-DF79-4613-95F7-5F84329FD581 wds:Q79765442-CB9C12F0-0302-47B9-9F25-5743DDF49FE8
author	Karel Pavelka Paul Emery Vibeke Strand Bernard Combe Edward Keystone
title	wds:Q79765442-B01EC6C2-7EFF-44C9-A1B1-CF75AFB9B114
title	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (en)
page(s)	wds:Q79765442-3EC08364-2420-4CA1-AF77-92A906AA7148
page(s)	3319-3329
instance of	wds:Q79765442-13BE4A37-1E8E-4292-878D-FF63978F9D1F
instance of	scholarly article
main subject	wds:Q79765442-9060A6B3-4EB8-4F16-A27B-F55CE0ADD8DC wds:Q79765442-B2113DCF-BEA8-4DD9-AFF3-F5324F07657D wds:Q79765442-BCFE0882-5BDC-4E6B-8B83-8118CE8C2A01
main subject	rheumatoid arthritis placebo wd:Q422232
PubMed ID	wds:Q79765442-EDFCA635-ABC8-43DF-A0AA-3BDE457B387F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18975346
PubMed ID	18975346
published in	wds:Q79765442-FB03B018-FE22-4316-8FEA-017430E9FCDB
published in	Arthritis and Rheumatism
issue	wds:Q79765442-13AE8385-911E-4AB7-BE3B-C46A722FCE8A
volume	wds:Q79765442-48D6C3F1-3142-4186-A8DC-3471A5458A12
issue	11
volume	58
DOI	wds:Q79765442-BB20A563-AE4E-43B9-9B47-EFDD02BCF93B
DOI	http://dx.doi.org/10.1002/ART.23964
DOI	10.1002/ART.23964
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q79765442
is cites work of	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Abatacept treatment for rheumatoid arthritis Use of biologics in rheumatoid arthritis: current and emerging paradigms of care Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis Adverse effects of biologics: a network meta-analysis and Cochrane overview Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis Pharmacotherapy options in rheumatoid arthritis American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Infectious complications associated with monoclonal antibodies and related small molecules Acute graft-versus-host disease: new treatment strategies Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis TNF inhibitor therapy for rheumatoid arthritis Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study How tumour necrosis factor blockers interfere with tuberculosis immunity. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics Advances in the treatment of polyarticular juvenile idiopathic arthritis Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective Immunological evaluation of rheumatoid arthritis patients treated with itolizumab Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software